Other News To Note
Wednesday, March 23, 2011
Tesaro Inc., of Boston, announced that it signed an agreement with Amgen Inc., of Thousand Oaks, Calif., that grants Tesaro exclusive worldwide rights for the development, manufacture, commercialization and distribution of small-molecule inhibitors of anaplastic lymphoma kinase (ALK). Tesaro said it plans to develop one or more compounds for oncology indications, including the treatment of patients with non-small-cell lung cancer whose tumors are ALK-positive.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.